Product: AKT2 Antibody
Catalog: AF6264
Description: Rabbit polyclonal antibody to AKT2
Application: WB IHC IF/ICC
Reactivity: Human, Mouse, Rat
Prediction: Pig, Zebrafish, Bovine, Horse, Chicken, Xenopus
Mol.Wt.: 60kDa; 56kD(Calculated).
Uniprot: P31751
RRID: AB_2835122

View similar products>>

   Size Price Inventory
 100ul $280 In stock
 200ul $350 In stock

Lead Time: Same day delivery

For pricing and ordering contact:
Local distributors

Product Info

Source:
Rabbit
Application:
WB 1:500-1:2000, IHC 1:50-1:200, IF/ICC 1:100-1:500
*The optimal dilutions should be determined by the end user.
*Tips:

WB: For western blot detection of denatured protein samples. IHC: For immunohistochemical detection of paraffin sections (IHC-p) or frozen sections (IHC-f) of tissue samples. IF/ICC: For immunofluorescence detection of cell samples. ELISA(peptide): For ELISA detection of antigenic peptide.

Reactivity:
Human,Mouse,Rat
Prediction:
Pig(100%), Zebrafish(91%), Bovine(100%), Horse(100%), Chicken(100%), Xenopus(100%)
Clonality:
Polyclonal
Specificity:
AKT2 Antibody detects endogenous levels of total AKT2.
RRID:
AB_2835122
Cite Format: Affinity Biosciences Cat# AF6264, RRID:AB_2835122.
Conjugate:
Unconjugated.
Purification:
The antiserum was purified by peptide affinity chromatography using SulfoLink™ Coupling Resin (Thermo Fisher Scientific).
Storage:
Rabbit IgG in phosphate buffered saline , pH 7.4, 150mM NaCl, 0.02% sodium azide and 50% glycerol. Store at -20 °C. Stable for 12 months from date of receipt.
Alias:

Fold/Unfold

Akt2; AKT2_HUMAN; HIHGHH; murine thymoma viral (v-akt) homolog-2; PKB; PKB beta; PKBB; PKBBETA; PRKBB; Protein kinase Akt 2; Protein kinase Akt-2; Protein kinase B beta; rac protein kinase beta; RAC-BETA; RAC-beta serine/threonine-protein kinase; RAC-PK-beta; v akt murine thymoma viral oncogene homolog 2;

Immunogens

Immunogen:
Uniprot:
Gene(ID):
Expression:
P31751 AKT2_HUMAN:

Expressed in all cell types so far analyzed.

Description:
Akt2 an AGC kinase. Plays critical roles in glucose metabolism and the development or maintenance of proper adipose tissue and islet mass for which other Akt/PKB isoforms are unable to fully compensate.
Sequence:
MNEVSVIKEGWLHKRGEYIKTWRPRYFLLKSDGSFIGYKERPEAPDQTLPPLNNFSVAECQLMKTERPRPNTFVIRCLQWTTVIERTFHVDSPDEREEWMRAIQMVANSLKQRAPGEDPMDYKCGSPSDSSTTEEMEVAVSKARAKVTMNDFDYLKLLGKGTFGKVILVREKATGRYYAMKILRKEVIIAKDEVAHTVTESRVLQNTRHPFLTALKYAFQTHDRLCFVMEYANGGELFFHLSRERVFTEERARFYGAEIVSALEYLHSRDVVYRDIKLENLMLDKDGHIKITDFGLCKEGISDGATMKTFCGTPEYLAPEVLEDNDYGRAVDWWGLGVVMYEMMCGRLPFYNQDHERLFELILMEEIRFPRTLSPEAKSLLAGLLKKDPKQRLGGGPSDAKEVMEHRFFLSINWQDVVQKKLLPPFKPQVTSEVDTRYFDDEFTAQSITITPPDRYDSLGLLELDQRTHFPQFSYSASIRE

Predictions

Predictions:

Score>80(red) has high confidence and is suggested to be used for WB detection. *The prediction model is mainly based on the alignment of immunogen sequences, the results are for reference only, not as the basis of quality assurance.

Species
Results
Score
Pig
100
Horse
100
Bovine
100
Xenopus
100
Chicken
100
Zebrafish
91
Sheep
0
Dog
0
Rabbit
0
Model Confidence:
High(score>80) Medium(80>score>50) Low(score<50) No confidence

PTMs - P31751 As Substrate

Site PTM Type Enzyme
M1 Acetylation
K14 Ubiquitination
K20 Ubiquitination
K30 Ubiquitination
S34 Phosphorylation
Y38 Phosphorylation
K39 Ubiquitination
T81 Phosphorylation
K111 Ubiquitination
Y122 Phosphorylation
C124 S-Nitrosylation
S126 Phosphorylation
S128 Phosphorylation
S131 Phosphorylation
S141 Phosphorylation
K142 Ubiquitination
K146 Ubiquitination
K156 Ubiquitination
K160 Ubiquitination
Y177 Phosphorylation
Y178 Phosphorylation
K185 Ubiquitination
K191 Ubiquitination
S242 Phosphorylation
K277 Ubiquitination
K285 Ubiquitination
K290 Ubiquitination
K298 Ubiquitination
S302 Phosphorylation
T306 Phosphorylation
T309 Phosphorylation Q15118 (PDK1) , O15530 (PDPK1) , P78527 (PRKDC)
T313 Phosphorylation
Y316 Phosphorylation
Y327 Phosphorylation
K378 Acetylation
K378 Ubiquitination
S379 Phosphorylation
K401 Ubiquitination
K427 Ubiquitination
Y438 Phosphorylation
S447 Phosphorylation
T449 Phosphorylation
T451 Phosphorylation
Y456 Phosphorylation
S458 Phosphorylation
S474 Phosphorylation O15530 (PDPK1) , P78527 (PRKDC)
Y475 Phosphorylation
S476 Phosphorylation
S478 Phosphorylation

PTMs - P31751 As Enzyme

Substrate Site Source
O15111 (CHUK) T23 Uniprot
O43464 (HTRA2) S212 Uniprot
O43524 (FOXO3) T32 Uniprot
O43524 (FOXO3) S253 Uniprot
O43524 (FOXO3) S315 Uniprot
O60331 (PIP5K1C) S555 Uniprot
P03372-1 (ESR1) S167 Uniprot
P04406 (GAPDH) T237 Uniprot
P04792 (HSPB1) S82 Uniprot
P15056 (BRAF) S364 Uniprot
P15056 (BRAF) S428 Uniprot
P15056 (BRAF) T440 Uniprot
P15311 (EZR) T567 Uniprot
P16220 (CREB1) S133 Uniprot
P28906 (CD34) S346 Uniprot
P29474 (NOS3) S615 Uniprot
P30405 (PPIF) S31 Uniprot
P35222 (CTNNB1) S552 Uniprot
P46527 (CDKN1B) T157 Uniprot
P49760 (CLK2) T344 Uniprot
P49815 (TSC2) S939 Uniprot
P49815 (TSC2) T1462 Uniprot
P49841 (GSK3B) S9 Uniprot
P55211 (CASP9) S196 Uniprot
P68431 (HIST1H3J) S11 Uniprot
P68431 (HIST1H3J) S29 Uniprot
P68431 (HIST1H3J) T46 Uniprot
P98170 (XIAP) S87 Uniprot
P98177 (FOXO4) T32 Uniprot
Q00987 (MDM2) S166 Uniprot
Q00987 (MDM2) S186 Uniprot
Q01860 (POU5F1) T235 Uniprot
Q09472 (EP300) S1834 Uniprot
Q12778 (FOXO1) T24 Uniprot
Q12778 (FOXO1) S256 Uniprot
Q13043 (STK4) T387 Uniprot
Q13188 (STK3) T117 Uniprot
Q13243 (SRSF5) S86 Uniprot
Q13541 (EIF4EBP1) T36 Uniprot
Q13541 (EIF4EBP1) T45 Uniprot
Q14315 (FLNC) S2233 Uniprot
Q15365 (PCBP1) S43 Uniprot
Q6ZWJ1 (STXBP4) S99 Uniprot
Q7Z6J0 (SH3RF1) S304 Uniprot
Q86YS7 (C2CD5) S197 Uniprot
Q8WX93 (PALLD) S1118 Uniprot
Q92908-2 (GATA6) S290 Uniprot
Q92934 (BAD) S99 Uniprot
Q92934 (BAD) S118 Uniprot
Q92945 (KHSRP) S193 Uniprot
Q96B36 (AKT1S1) T246 Uniprot
Q96F86 (EDC3) S161 Uniprot
Q99683 (MAP3K5) S83 Uniprot
Q99697 (PITX2) T90 Uniprot
Q9GZV1 (ANKRD2) S99 Uniprot
Q9H0H5 (RACGAP1) T249 Uniprot
Q9H0K1 (SIK2) S358 Uniprot
Q9NZJ5 (EIF2AK3) T802 Uniprot
Q9UBK2 (PPARGC1A) S571 Uniprot
Q9Y3M2 (CBY1) S20 Uniprot
Q9Y4I1 (MYO5A) T1650 Uniprot

Research Backgrounds

Function:

AKT2 is one of 3 closely related serine/threonine-protein kinases (AKT1, AKT2 and AKT3) called the AKT kinase, and which regulate many processes including metabolism, proliferation, cell survival, growth and angiogenesis. This is mediated through serine and/or threonine phosphorylation of a range of downstream substrates. Over 100 substrate candidates have been reported so far, but for most of them, no isoform specificity has been reported. AKT is responsible of the regulation of glucose uptake by mediating insulin-induced translocation of the SLC2A4/GLUT4 glucose transporter to the cell surface. Phosphorylation of PTPN1 at 'Ser-50' negatively modulates its phosphatase activity preventing dephosphorylation of the insulin receptor and the attenuation of insulin signaling. Phosphorylation of TBC1D4 triggers the binding of this effector to inhibitory 14-3-3 proteins, which is required for insulin-stimulated glucose transport. AKT regulates also the storage of glucose in the form of glycogen by phosphorylating GSK3A at 'Ser-21' and GSK3B at 'Ser-9', resulting in inhibition of its kinase activity. Phosphorylation of GSK3 isoforms by AKT is also thought to be one mechanism by which cell proliferation is driven. AKT regulates also cell survival via the phosphorylation of MAP3K5 (apoptosis signal-related kinase). Phosphorylation of 'Ser-83' decreases MAP3K5 kinase activity stimulated by oxidative stress and thereby prevents apoptosis. AKT mediates insulin-stimulated protein synthesis by phosphorylating TSC2 at 'Ser-939' and 'Thr-1462', thereby activating mTORC1 signaling and leading to both phosphorylation of 4E-BP1 and in activation of RPS6KB1. AKT is involved in the phosphorylation of members of the FOXO factors (Forkhead family of transcription factors), leading to binding of 14-3-3 proteins and cytoplasmic localization. In particular, FOXO1 is phosphorylated at 'Thr-24', 'Ser-256' and 'Ser-319'. FOXO3 and FOXO4 are phosphorylated on equivalent sites. AKT has an important role in the regulation of NF-kappa-B-dependent gene transcription and positively regulates the activity of CREB1 (cyclic AMP (cAMP)-response element binding protein). The phosphorylation of CREB1 induces the binding of accessory proteins that are necessary for the transcription of pro-survival genes such as BCL2 and MCL1. AKT phosphorylates 'Ser-454' on ATP citrate lyase (ACLY), thereby potentially regulating ACLY activity and fatty acid synthesis. Activates the 3B isoform of cyclic nucleotide phosphodiesterase (PDE3B) via phosphorylation of 'Ser-273', resulting in reduced cyclic AMP levels and inhibition of lipolysis. Phosphorylates PIKFYVE on 'Ser-318', which results in increased PI(3)P-5 activity. The Rho GTPase-activating protein DLC1 is another substrate and its phosphorylation is implicated in the regulation cell proliferation and cell growth. AKT plays a role as key modulator of the AKT-mTOR signaling pathway controlling the tempo of the process of newborn neurons integration during adult neurogenesis, including correct neuron positioning, dendritic development and synapse formation. Signals downstream of phosphatidylinositol 3-kinase (PI(3)K) to mediate the effects of various growth factors such as platelet-derived growth factor (PDGF), epidermal growth factor (EGF), insulin and insulin-like growth factor I (IGF-I). AKT mediates the antiapoptotic effects of IGF-I. Essential for the SPATA13-mediated regulation of cell migration and adhesion assembly and disassembly. May be involved in the regulation of the placental development.

One of the few specific substrates of AKT2 identified recently is PITX2. Phosphorylation of PITX2 impairs its association with the CCND1 mRNA-stabilizing complex thus shortening the half-life of CCND1. AKT2 seems also to be the principal isoform responsible of the regulation of glucose uptake. Phosphorylates C2CD5 on 'Ser-197' during insulin-stimulated adipocytes. AKT2 is also specifically involved in skeletal muscle differentiation, one of its substrates in this process being ANKRD2. Down-regulation by RNA interference reduces the expression of the phosphorylated form of BAD, resulting in the induction of caspase-dependent apoptosis. Phosphorylates CLK2 on 'Thr-343'.

PTMs:

Phosphorylation on Thr-309 and Ser-474 is required for full activity.

Ubiquitinated; undergoes both 'Lys-48'- and 'Lys-63'-linked polyubiquitination. TRAF6-induced 'Lys-63'-linked AKT2 ubiquitination. When fully phosphorylated and translocated into the nucleus, undergoes 'Lys-48'-polyubiquitination catalyzed by TTC3, leading to its degradation by the proteasome.

O-GlcNAcylation at Thr-306 and Thr-313 inhibits activating phosphorylation at Thr-309 via disrupting the interaction between AKT and PDK1.

Subcellular Location:

Cytoplasm. Nucleus. Cell membrane>Peripheral membrane protein. Early endosome.
Note: Localizes within both nucleus and cytoplasm of proliferative primary myoblasts and mostly within the nucleus of differentiated primary myoblasts. By virtue of the N-terminal PH domain, is recruited to sites of the plasma membrane containing increased PI(3,4,5)P3 or PI(3,4)P2, cell membrane targeting is also facilitared by interaction with CLIP3. Colocalizes with WDFY2 in early endosomes (By similarity).

Extracellular region or secreted Cytosol Plasma membrane Cytoskeleton Lysosome Endosome Peroxisome ER Golgi apparatus Nucleus Mitochondrion Manual annotation Automatic computational assertionSubcellular location
Tissue Specificity:

Expressed in all cell types so far analyzed.

Subunit Structure:

Interacts with BTBD10 (By similarity). Interacts with KCTD20 (By similarity). Interacts (via PH domain) with MTCP1, TCL1A AND TCL1B. Interacts with CLK2, PBH2 and TRAF6. Interacts (when phosphorylated) with CLIP3, the interaction promotes cell membrane localization. Interacts with WDFY2 (via WD repeats 1-3).

Family&Domains:

Binding of the PH domain to phosphatidylinositol 3,4,5-trisphosphate (PI(3,4,5)P3) following phosphatidylinositol 3-kinase alpha (PIK3CA) activity results in its targeting to the plasma membrane.

Belongs to the protein kinase superfamily. AGC Ser/Thr protein kinase family. RAC subfamily.

Research Fields

· Cellular Processes > Transport and catabolism > Autophagy - animal.   (View pathway)

· Cellular Processes > Cell growth and death > Apoptosis.   (View pathway)

· Cellular Processes > Cell growth and death > Cellular senescence.   (View pathway)

· Cellular Processes > Cellular community - eukaryotes > Focal adhesion.   (View pathway)

· Cellular Processes > Cellular community - eukaryotes > Signaling pathways regulating pluripotency of stem cells.   (View pathway)

· Environmental Information Processing > Signal transduction > MAPK signaling pathway.   (View pathway)

· Environmental Information Processing > Signal transduction > ErbB signaling pathway.   (View pathway)

· Environmental Information Processing > Signal transduction > Ras signaling pathway.   (View pathway)

· Environmental Information Processing > Signal transduction > Rap1 signaling pathway.   (View pathway)

· Environmental Information Processing > Signal transduction > cGMP-PKG signaling pathway.   (View pathway)

· Environmental Information Processing > Signal transduction > cAMP signaling pathway.   (View pathway)

· Environmental Information Processing > Signal transduction > HIF-1 signaling pathway.   (View pathway)

· Environmental Information Processing > Signal transduction > FoxO signaling pathway.   (View pathway)

· Environmental Information Processing > Signal transduction > Sphingolipid signaling pathway.   (View pathway)

· Environmental Information Processing > Signal transduction > Phospholipase D signaling pathway.   (View pathway)

· Environmental Information Processing > Signal transduction > mTOR signaling pathway.   (View pathway)

· Environmental Information Processing > Signal transduction > PI3K-Akt signaling pathway.   (View pathway)

· Environmental Information Processing > Signal transduction > AMPK signaling pathway.   (View pathway)

· Environmental Information Processing > Signal transduction > Apelin signaling pathway.   (View pathway)

· Environmental Information Processing > Signal transduction > Jak-STAT signaling pathway.   (View pathway)

· Environmental Information Processing > Signal transduction > TNF signaling pathway.   (View pathway)

· Human Diseases > Drug resistance: Antineoplastic > EGFR tyrosine kinase inhibitor resistance.

· Human Diseases > Drug resistance: Antineoplastic > Endocrine resistance.

· Human Diseases > Drug resistance: Antineoplastic > Platinum drug resistance.

· Human Diseases > Endocrine and metabolic diseases > Insulin resistance.

· Human Diseases > Endocrine and metabolic diseases > Non-alcoholic fatty liver disease (NAFLD).

· Human Diseases > Infectious diseases: Parasitic > Chagas disease (American trypanosomiasis).

· Human Diseases > Infectious diseases: Parasitic > Toxoplasmosis.

· Human Diseases > Infectious diseases: Bacterial > Tuberculosis.

· Human Diseases > Infectious diseases: Viral > Hepatitis C.

· Human Diseases > Infectious diseases: Viral > Hepatitis B.

· Human Diseases > Infectious diseases: Viral > Measles.

· Human Diseases > Infectious diseases: Viral > Influenza A.

· Human Diseases > Infectious diseases: Viral > Human papillomavirus infection.

· Human Diseases > Infectious diseases: Viral > HTLV-I infection.

· Human Diseases > Infectious diseases: Viral > Epstein-Barr virus infection.

· Human Diseases > Cancers: Overview > Pathways in cancer.   (View pathway)

· Human Diseases > Cancers: Overview > Proteoglycans in cancer.

· Human Diseases > Cancers: Specific types > Colorectal cancer.   (View pathway)

· Human Diseases > Cancers: Specific types > Renal cell carcinoma.   (View pathway)

· Human Diseases > Cancers: Specific types > Pancreatic cancer.   (View pathway)

· Human Diseases > Cancers: Specific types > Endometrial cancer.   (View pathway)

· Human Diseases > Cancers: Specific types > Glioma.   (View pathway)

· Human Diseases > Cancers: Specific types > Prostate cancer.   (View pathway)

· Human Diseases > Cancers: Specific types > Melanoma.   (View pathway)

· Human Diseases > Cancers: Specific types > Chronic myeloid leukemia.   (View pathway)

· Human Diseases > Cancers: Specific types > Acute myeloid leukemia.   (View pathway)

· Human Diseases > Cancers: Specific types > Small cell lung cancer.   (View pathway)

· Human Diseases > Cancers: Specific types > Non-small cell lung cancer.   (View pathway)

· Human Diseases > Cancers: Specific types > Breast cancer.   (View pathway)

· Human Diseases > Cancers: Specific types > Hepatocellular carcinoma.   (View pathway)

· Human Diseases > Cancers: Specific types > Gastric cancer.   (View pathway)

· Human Diseases > Cancers: Overview > Central carbon metabolism in cancer.   (View pathway)

· Human Diseases > Cancers: Overview > Choline metabolism in cancer.   (View pathway)

· Organismal Systems > Immune system > Chemokine signaling pathway.   (View pathway)

· Organismal Systems > Aging > Longevity regulating pathway.   (View pathway)

· Organismal Systems > Aging > Longevity regulating pathway - multiple species.   (View pathway)

· Organismal Systems > Circulatory system > Adrenergic signaling in cardiomyocytes.   (View pathway)

· Organismal Systems > Development > Osteoclast differentiation.   (View pathway)

· Organismal Systems > Immune system > Platelet activation.   (View pathway)

· Organismal Systems > Immune system > Toll-like receptor signaling pathway.   (View pathway)

· Organismal Systems > Immune system > T cell receptor signaling pathway.   (View pathway)

· Organismal Systems > Immune system > B cell receptor signaling pathway.   (View pathway)

· Organismal Systems > Immune system > Fc epsilon RI signaling pathway.   (View pathway)

· Organismal Systems > Immune system > Fc gamma R-mediated phagocytosis.   (View pathway)

· Organismal Systems > Nervous system > Neurotrophin signaling pathway.   (View pathway)

· Organismal Systems > Nervous system > Cholinergic synapse.

· Organismal Systems > Nervous system > Dopaminergic synapse.

· Organismal Systems > Endocrine system > Insulin signaling pathway.   (View pathway)

· Organismal Systems > Endocrine system > Progesterone-mediated oocyte maturation.

· Organismal Systems > Endocrine system > Estrogen signaling pathway.   (View pathway)

· Organismal Systems > Endocrine system > Prolactin signaling pathway.   (View pathway)

· Organismal Systems > Endocrine system > Thyroid hormone signaling pathway.   (View pathway)

· Organismal Systems > Endocrine system > Adipocytokine signaling pathway.

· Organismal Systems > Endocrine system > Glucagon signaling pathway.

· Organismal Systems > Endocrine system > Regulation of lipolysis in adipocytes.

· Organismal Systems > Endocrine system > Relaxin signaling pathway.

· Organismal Systems > Digestive system > Carbohydrate digestion and absorption.

References

1). MicroRNA-137 inhibits pituitary prolactinoma proliferation by targeting AKT2. Journal of Endocrinological Investigation, 2022 (PubMed: 36427136) [IF=5.4]

2). Long non-coding RNA LINC00460 promotes proliferation and inhibits apoptosis of cervical cancer cells by targeting microRNA-503-5p. MOLECULAR AND CELLULAR BIOCHEMISTRY, 2020 (PubMed: 32740791) [IF=4.3]

Application: WB    Species: human    Sample: SiHa and HeLa cells

Fig. 4 | LINC00460 acts as a competing endogenous RNA of miR503-5p in SiHa and HeLa cells.d–h Expressions of AKT2,HMGA2 and SHOX2 in SiHa and HeLa cells by western blotting.**p<0.01 versus cells co-transfected with wild-type LINC00460 and miR-503-5p mimic. ##p<0.01 versus cells transfected with NC shRNA. WT wild-type LINC00460, MUT mutated LINC00460

3). L-Borneol 7-O-[β-D-Apiofuranosyl-(16)]-β-D-Glucopyranoside Alleviates Myocardial Ischemia-Reperfusion Injury in Rats and Hypoxic/Reoxygenated Injured Myocardial Cells via Regulating the PI3K/AKT/mTOR Signaling Pathway. Journal of Immunology Research, 2022 (PubMed: 35600046) [IF=4.1]

Application: WB    Species: Rat    Sample:

Figure 5 Effect of LBAG on the expression of autophagy and PI3K/AKT pathway-related proteins in rats. (a) Representative protein blots of p62, LC3, and Beclin 1. (b) Quantitative analysis of p62, LC3, and Beclin 1 proteins. (c) Representative protein blots of PI3K/AKT pathway-related proteins. (d) Quantitative analysis of PI3K pathway-related targets in each group. ∗P < 0.05 and ∗∗P < 0.01 vs. sham group. ▲P < 0.05 and ▲▲P < 0.01 vs. IR group.

4). Radix Actinidia chinensis Suppresses Renal Cell Carcinoma Progression: Network Pharmacology Prediction and In Vivo Experimental Validation. Analytical Cellular Pathology, 2022 (PubMed: 35942173) [IF=3.2]

Application: WB    Species: Mice    Sample: tumor cell

Figure 8 RAC prevented the activation of the PI3K/AKT/mTOR and MAPK pathway. The phosphorylation of PI3K, AKT, and mTOR (a) and P38 and ERK (b) was measured by western blot. ▲P < 0.05 and ▲▲P < 0.01vs. the model. Results were presented as mean ± SD. n = 3. Note: RAC: Radix Actinidia chinensis; RCC: renal cell carcinoma.

5). TMT-Based Quantitative Proteomics Reveals Cochlear Protein Profile Alterations in Mice with Noise-Induced Hearing Loss. International Journal of Environmental Research and Public Health, 2021 (PubMed: 35010640)

Application: WB    Species: Mice    Sample:

Figure 5 Measurement of expression levels of DEPs, oxidative stress markers and proinflammatory cytokines production. (a) Validation of representative inflammation and autophagy-related DEPs by western blots in the control group (n = 3) and noise group (n = 3). (b) Comparison of MDA level and SOD activity in cochlea between the control group (n = 3) and noise group (n = 3). (c) Comparison of proinflammatory cytokines TNF-α and IL-6 in cochlea between the control group (n = 3) and noise group (n = 3). Data are represented as mean ± SD. * p < 0.05, ** p < 0.01.

Restrictive clause

 

Affinity Biosciences tests all products strictly. Citations are provided as a resource for additional applications that have not been validated by Affinity Biosciences. Please choose the appropriate format for each application and consult Materials and Methods sections for additional details about the use of any product in these publications.

For Research Use Only.
Not for use in diagnostic or therapeutic procedures. Not for resale. Not for distribution without written consent. Affinity Biosciences will not be held responsible for patent infringement or other violations that may occur with the use of our products. Affinity Biosciences, Affinity Biosciences Logo and all other trademarks are the property of Affinity Biosciences LTD.